[go: up one dir, main page]

PE20001331A1 - Identificacion de genotipos senv - Google Patents

Identificacion de genotipos senv

Info

Publication number
PE20001331A1
PE20001331A1 PE1999001137A PE00113799A PE20001331A1 PE 20001331 A1 PE20001331 A1 PE 20001331A1 PE 1999001137 A PE1999001137 A PE 1999001137A PE 00113799 A PE00113799 A PE 00113799A PE 20001331 A1 PE20001331 A1 PE 20001331A1
Authority
PE
Peru
Prior art keywords
seq
dna
virus
orf
nucleotides
Prior art date
Application number
PE1999001137A
Other languages
English (en)
Inventor
Daniele Primi
Gianfranco Fiordalisi
Giovanni Lorenzo Mantero
Sonia Mattioli
Alessandra Sottini
Fabrizio Bonelli
Laura Vaglini
Paolo Olivero
Andrea Corso
Marco Bonelli
Original Assignee
Diasorin S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI982437 external-priority patent/IT1303732B1/it
Priority claimed from ITMI990923 external-priority patent/IT1312552B1/it
Application filed by Diasorin S R L filed Critical Diasorin S R L
Publication of PE20001331A1 publication Critical patent/PE20001331A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UN ADN DE UN VIRUS QUE: a)CONTIENE COMO MINIMO UN ORF QUE CODIFICA UN POLIPEPTIDO DE SEQ ID NO 21, ENTRE OTROS; b)INCLUYE LA SECUENCIA DE ADN DE SEQ ID NO 2, ENTRE OTROS; c)COMPRENDE PORCIONES COMO MINIMO DE 80 NUCLEOTIDOS QUE HIBRIDAN EN CONDICIONES RESTRICTIVAS CON LA HEBRA COMPLEMENTARIA DEL ADN DE LA SEQ ID NO 26, ENTRE OTROS; d)ES DEGENERADA CON RESPECTO AL ADN ANTERIOR PERO NO HIBRIDA CON LA HEBRA COMPLEMENTARIA DEL GENOMA DEL VIRUS TT; e)ES COMO MINIMO 50% DEL ADN DE LA SEQ ID NO 26, ENTRE OTROS O CONTIENE UN ORF O UN FRAGMENTO DEL MISMO QUE ES COMO MINIMO 50% DE SEQ ID NO 28, ENTRE OTROS; f)PARTES DE ELLA PUEDEN AMPLIFICARSE POR PCR EN CONDICIONES ADECUADAS UTILIZANDO OLIGONUCLEOTIDOS INICIADORES DEFINIDOS EN SEQ ID NO 41, ENTRE OTROS; O LA CADENA COMPLEMENTARIA TAL COMO UN OLIGOPEPTIDO; g)SE DERIVA DE CUALQUIERA DE LAS MOLECULAS ANTERIORES POR INSERCION, SUSTITUCION, DELECION, INVERSION, DUPLICACION, RECOMBINACION, ADICION O UNA COMBINACION; CARACTERIZADO POR CODIFICAR 12 NUCLEOTIDOS, EL QUE CODIFICA UN EPITOPO QUE REACCIONA CON ANTICUERPOS PARA EL VIRUS SEN, INICIADOR O UNA SONDA. TAMBIEN SE REFIERE A UN METODO PARA PRODUCIR Y DETECTARUN POLIPEPTIDO, VIRUS, ANTICUERPO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE HEPATOPATIAS (HEPATITIS), ENFERMEDAD INFLAMATORIA, (LUPUS) TRASTORNOS PROLIFERATIVOS (CANCER)
PE1999001137A 1998-11-10 1999-11-10 Identificacion de genotipos senv PE20001331A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI982437 IT1303732B1 (it) 1998-11-10 1998-11-10 Molecole di acido nucleico che rappresentano un virus trasmissibileper via parenterale.
ITMI990923 IT1312552B1 (it) 1999-04-30 1999-04-30 Molecole di acido nucleico che rappresentano un virus trasmissibileper via parenterale
EP99830298 1999-05-14
EP99113932 1999-07-16

Publications (1)

Publication Number Publication Date
PE20001331A1 true PE20001331A1 (es) 2000-12-19

Family

ID=27443821

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001137A PE20001331A1 (es) 1998-11-10 1999-11-10 Identificacion de genotipos senv

Country Status (8)

Country Link
EP (1) EP1137779A2 (es)
JP (1) JP2002529092A (es)
AR (1) AR021143A1 (es)
AU (1) AU1381600A (es)
NO (1) NO20012276L (es)
PE (1) PE20001331A1 (es)
TN (1) TNSN99210A1 (es)
WO (1) WO2000028039A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020065559A (ko) * 1999-12-10 2002-08-13 로셰 디아그노스틱스 게엠베하 센티넬 바이러스 ｉ형 간염 바이러스 (ｓｖⅰ)
DE10007234A1 (de) * 2000-02-17 2001-10-18 Sension Biolog Detektions Und Peptid und dafür kodierende Nukleinsäure zur Bestimmung, Diagnostik und Therapie von Erkrankungen des Nervensystems
DE10144346A1 (de) * 2001-09-10 2003-04-03 Deutsches Krebsforsch TT-Virus-Sequenzen in menschlichen Tumorgeweben, Mittel zu deren Nachweis sowie Tumortherapie
DK2399928T3 (da) * 2010-06-23 2018-01-29 Deutsches Krebsforsch Specifikke TT-virus-sekvenser og kimæriske TT-virusværtscelle-DNA-molekyler til anvendelse ved diagnosticering, forebyggelse og behandling af cancer og auto-immunitet
US20110318363A1 (en) 2010-06-23 2011-12-29 Deutsches Krebsforschungszentrum Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
US9676828B2 (en) 2010-06-23 2017-06-13 Deutsches Krebsforschungszentrum Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
SI2585477T1 (sl) * 2010-06-23 2019-03-29 Deutsches Krebsforschungszentrum Preurejene tt virusne molekule za uporabo v diagnozi, preprečevanje in zdravljenje raka in avtoimunosti

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837437D1 (de) * 1997-07-25 2007-05-10 Tamura Ryoji Gen, polynukleotid, polypeptid und virion des non-b, non-c, non-g-hepatitis virus, eine methode zur abtrennung dieses virions und methoden für die virusdetektion.
WO1999058638A2 (en) * 1998-05-13 1999-11-18 Innogenetics N.V. Sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections

Also Published As

Publication number Publication date
WO2000028039A3 (en) 2000-10-05
AU1381600A (en) 2000-05-29
NO20012276L (no) 2001-07-09
TNSN99210A1 (fr) 2005-11-10
WO2000028039A2 (en) 2000-05-18
JP2002529092A (ja) 2002-09-10
AR021143A1 (es) 2002-06-12
NO20012276D0 (no) 2001-05-09
EP1137779A2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
Rezelj et al. Defective viral genomes as therapeutic interfering particles against flavivirus infection in mammalian and mosquito hosts
Menachery et al. Combination attenuation offers strategy for live attenuated coronavirus vaccines
Ridpath et al. Delayed onset postvaccinal mucosal disease as a result of genetic recombination between genotype 1 and genotype 2 BVDV
Jones et al. Genetic typing of bovine viral diarrhea virus isolates from Argentina
ES2176342T3 (es) Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacioncomo agentes profilacticos, terapeuticos y de diagnostico.
Ridpath et al. Comparison of the complete genomic sequence of the border disease virus, BD31, to other pestiviruses
ES2075901T3 (es) Sistemas de expresion de virus recombinantes de arn con cadena negativa y vacunas.
MX9700817A (es) Secuencia viral de nucleotidos de "vr-2332" y metodos de uso.
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
HUP0203305A2 (hu) Fertőző klónok
Vilček et al. Cellular insertions in the NS2-3 genome region of cytopathic bovine viral diarrhoea virus (BVDV) isolates
PE20001331A1 (es) Identificacion de genotipos senv
WO2002072802A3 (en) Live attenuated strains of prrs virus
Kleine Büning et al. Nonreplicative RNA recombination of an animal plus-strand RNA virus in the absence of efficient translation of viral proteins
Broto et al. Type I interferon acts as a major barrier to the establishment of persistent infectious Bursal disease virus infections
CA2430582A1 (en) A method for in vitro molecular evolution of protein function
KR970706399A (ko) 약독화 바이러스 및 그 제조 방법(attenuated viruses and method of making the same)
DK0727483T3 (da) Retrovirus fra HIV-gruppen og dens anvendelse
Haas et al. Analysis of the H gene, the central untranslated region and the proximal coding part of the F gene of wild-type and vaccine canine distemper viruses
DK1151079T3 (da) 1-deoxy-D-xylulose-5-phosphatreduktoisomerase og anvendelsesfremgangsmåder
ES2286212T3 (es) Secuencias suprimidas especificamente del genoma de mycobacterium tuberculosis, y su uso en el diagnostico y como vacunas.
Desport et al. Genome instability in BVDV: an examination of the sequence and structural influences on RNA recombination
Miller et al. Replication-competent recombinant porcine reproductive and respiratory syndrome (PRRS) virus expressing antiviral cytokine interferon-ω5 as a modified live virus vaccine
Banks DNA restriction fragment length polymorphism among British isolates of Aujeszky's disease virus: use of the polymerase chain reaction to discriminate among strains
AR024122A1 (es) Metodo para la estabilizacion intensificada de proteinas y produccion de lineas celulares que sirven para la produccion de dichas proteinas estabilizadas

Legal Events

Date Code Title Description
FC Refusal